HeartBeam Inc. Advances Toward Commercialization with Promising Q1 2025 Results
Summary by citybuzz.co
1 Articles
1 Articles
All
Left
Center
Right
HeartBeam Inc. Advances Toward Commercialization with Promising Q1 2025 Results
HeartBeam Inc. (NASDAQ: BEAT) has announced its financial results and operational highlights for the first quarter of 2025, showcasing significant strides toward the commercialization of its groundbreaking 12-lead ECG synthesis software. The company’s VALID-ECG pivotal study achieved a 93.4% diagnostic agreement with standard ECGs, a milestone that underscores the potential of HeartBeam’s technology to revolutionize cardiac care outside traditio…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium